Lirilumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia

Clinical trial NCT02399917 · TERMINATED

Trial details

NCT number: NCT02399917
Sponsor: M.D. Anderson Cancer Center
Status: TERMINATED
Phase: Phase 2
Study type: INTERVENTIONAL

Acute Biphenotypic Leukemia Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome Recurrent Acute Myeloid Leukemia Refractory Acute Myeloid Leukemia

Start date: 2015-04-20
Primary completion: 2018-07-12
Enrollment: 36

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.